Home / Business and Economy / Vertex Pharma Profits Soar on Cystic Fibrosis Drug Sales
Vertex Pharma Profits Soar on Cystic Fibrosis Drug Sales
5 May
Summary
- Vertex Pharmaceuticals reported a significant profit beat, driven by a nearly eight-fold increase in Alyftrek sales.
- Alyftrek, a new once-daily triple combination therapy for cystic fibrosis, generated $424.4 million in sales.
- Despite strong performance from new drugs, older drug Trikafta missed analyst revenue expectations in the first quarter.
Vertex Pharmaceuticals exceeded first-quarter profit expectations, bolstered by substantial sales growth from its latest cystic fibrosis therapy. The new once-daily treatment, Alyftrek, achieved $424.4 million in sales during the quarter, marking an impressive increase from $53.9 million in the previous year following its December 2024 approval.
While the company's established drug, Trikafta, generated $2.35 billion, it fell short of the $2.64 billion anticipated by analysts. Vertex reaffirmed its full-year revenue guidance, projecting between $12.95 billion and $13.1 billion.
The Boston-based company reported a 8% rise in quarterly revenue to $2.99 billion. Its pain treatment, Journavx, has seen significant adoption since its March 2025 launch, with over 1 million prescriptions filled, contributing $29 million in revenue in the first quarter of 2026.
